Cognitive impairment and electroconvulsive therapy in geriatric depression, what could be the role of rivastigmine? A case series
Electroconvulsive therapy (ECT), albeit highly effective in treating depression, is frequently associated with cognitive impairment, either temporary or more persistent. Especially in older patients, who generally respond even better, serious cognitive impairment during the course of ECT may lead to...
Main Authors: | Audrey Monica van Schaik, Didi Rhebergen, Marieke Jantien Henstra, Daniel J. Kadouch, Eric van Exel, Maximilianus Lourentius Stek |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-09-01
|
Series: | Clinics and Practice |
Subjects: | |
Online Access: | https://www.clinicsandpractice.org/index.php/cp/article/view/780 |
Similar Items
-
Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods
by: Marieke J. Henstra, et al.
Published: (2022-07-01) -
The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
by: Tahereh Jamshidnejad-Tosaramandani, et al.
Published: (2021-11-01) -
Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model
by: Maciej Zadrozny, et al.
Published: (2024-04-01) -
Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease
by: David Vicente-Zurdo, et al.
Published: (2022-06-01) -
Rivastigmine–Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors
by: Jie Wu, et al.
Published: (2023-12-01)